Bronstein, Gewirtz & Grossman, LLC announces an investigation against Akero Therapeutics, Inc. (Akro) and encourages shareholders to learn more about the examination

New York City, NY / Access Newswire / March 6, 2025 / Bronstein, Gewirtz & Grossman, LLC examines potential claims in the name of buyers of Akero Therapeutics, Inc. (“Akero” or “The Company”) (Nasdaq: Akro). Investors who bought Akero Securities before September 13, 2022 and continue to stick to the present are encouraged to obtain additional information and support the examination by visiting the company's website: bgandg..com/akro.

Investigative details

The investigation concerns whether Akero and certain of his leaders and/or directors have involved the misconduct of companies.

What's next?

If you have information about facts about this investigation or have bought Akero shares, you can support this investigation by visiting the company's website: bgandg..com/akro. You can also contact Peretz Bronstein or his customer relationship manager Nathan Miller from Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There are no costs for you

We represent investors in collective lawsuits on a eventual fee. This means that we will ask the court to refund ourselves for expenses and legal fees, usually a percentage of the entire recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized company that represents investors in collecting lawsuits for securities fraud and shareholder derivative lawsuits. Our company has recovered hundreds of million dollars for investors nationwide.

Follow us to updates to updates too LinkedInPresent XPresent Facebookor Instagram.

Lawyer advertising. Earlier results do not guarantee similar results.

contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC

See the original press release on Access Newswire